FIELD: medicine.
SUBSTANCE: group of inventions relates to methods of treating chronic pouch ileitis. Methods provide for administering to a subject a therapeutically effective dose of 300 mg of a humanized antibodies α4β7, particularly vedolizumab, and oral corticosteroid therapy in a subject. Human subject has an endoscopic sub-score of pouchitis disease activity index (PDAI) equal to 6 at selection or has a modified pouchitis disease activity index (mPDAI) ≥ 5 and endoscopic subpoint ≥2 at selection, and was subjected to proctocolectomy with formation of ileal pouch anal anastomosis (IPAA) in ulcerative colitis, and has insufficiently complete response, loss of response or intolerance to antibiotic treatment.
EFFECT: inventions enable to achieve remission of disease in 14 weeks after the initial dose of the antibody with achievement of mPDAI < 5, and reducing the mPDAI score by ≥2 from the initial level.
21 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF PEDIATRIC DISORDERS/DISEASES | 2018 |
|
RU2778567C2 |
| DOSES AND ADMINISTRATION OF ANTIBODIES AGAINST C5 FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) | 2020 |
|
RU2822664C2 |
| APPLICATION OF AN ANTIBODY TO PD-1 IN COMBINATION WITH FAMITINIB FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING TUMOURS | 2019 |
|
RU2783846C1 |
| METHODS FOR INCREASING VACCINE EFFICIENCY BY INJECTING IL-4R ANTAGONIST | 2017 |
|
RU2753869C2 |
| TIGIT ANTIBODY ADMINISTRATION REGIMEN FOR TREATING CANCER | 2019 |
|
RU2833669C2 |
| METHODS OF DIAGNOSING AND TREATING RHEUMATOID ARTHRITIS | 2020 |
|
RU2828027C2 |
| ANTIBODIES, USE THEREOF AND METHODS OF USE THEREOF | 2016 |
|
RU2838031C1 |
| TREATING LIVER DISEASE OR DISORDER INVOLVING USE OF ACTRII RECEPTOR ANTAGONISTS | 2020 |
|
RU2838150C1 |
| METHODS OF TREATING OR PREVENTING ASTHMA BY ADMINISTERING IL-4R ANTAGONIST | 2020 |
|
RU2832774C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
